Precision oncology trials based on cancer biomarkers have the potential to improve outcomes by guiding the optimal choice of therapies for patients. For this to be truly achieved, computational methods such as virtual molecular tumor boards, dynamic precision medicine and digital twins are needed to support cohort selection and trial enrollment at scale.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Experimental Hematology & Oncology Open Access 31 October 2022
-
How artificial intelligence might disrupt diagnostics in hematology in the near future
Oncogene Open Access 08 June 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Prasad, V., Fojo, T. & Brada, M. Lancet Oncol. 17, e81–e86 (2016).
Esserman, L.J. et al. J. Clin. Oncol. https://doi.org/10.1200/jco.2009.27.18_suppl.lba515 (2009).
McNeil, C. J. Natl. Cancer Inst. 107, djv193 (2015).
Liu, J. et al. Cell 173, 400–416.e11 (2018).
Edwards, N. J. et al. J. Proteome Res. 14, 2707–2713 (2015).
Rozenblatt-Rosen, O. et al. Cell 181, 236–249 (2020).
Rolfo, C. et al. ESMO Open 3, e000398 (2018).
Rao, S. et al. JCO Clin. Cancer Inform. 4, 602–613 (2020).
Pishvaian, M. J. et al. JAMIA Open 2, 505–515 (2019).
Lamping, M. et al. Eur. J. Cancer 127, 41–51 (2020).
Beckman, R. A., Schemmann, G. S. & Yeang, C.-H. Proc. Natl Acad. Sci. USA 109, 14586–14591 (2012).
Alber, M. et al. NPJ Digit. Med. 2, 115 (2019).
Rasheed, A., San, O. & Kvamsdal, T. arXiv https://arxiv.org/abs/1910.01719 (2019).
Kim, E., Rebecca, V. W., Smalley, K. S. M. & Anderson, A. R. A. Eur. J. Cancer 67, 213–222 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.R.B. reports personal fees (consulting fee) from Perthera.
Rights and permissions
About this article
Cite this article
Madhavan, S., Beckman, R.A., McCoy, M.D. et al. Envisioning the future of precision oncology trials. Nat Cancer 2, 9–11 (2021). https://doi.org/10.1038/s43018-020-00163-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00163-8
This article is cited by
-
A federated learning system for precision oncology in Europe: DigiONE
Nature Medicine (2024)
-
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Experimental Hematology & Oncology (2022)
-
How artificial intelligence might disrupt diagnostics in hematology in the near future
Oncogene (2021)